{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:27:36Z","timestamp":1792520856472,"version":"4.5.0"},"reference-count":147,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:00:00Z","timestamp":1533859200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50-100007, PO1-155258, RO1-50947"],"award-info":[{"award-number":["P50-100007, PO1-155258, RO1-50947"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01821","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T04:37:10Z","timestamp":1533875830000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":272,"title":["Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Shih-Feng","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tzu","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosinol","year":"2012","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1586\/17474086.2014.882764","article-title":"Current strategies for treatment of relapsed\/refractory multiple myeloma","volume":"7","author":"Laubach","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1158\/0008-5472.CAN-11-2067","article-title":"Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1","volume":"72","author":"Fowler","year":"2012","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1182\/blood-2003-04-1338","article-title":"Endothelial cells in the bone marrow of patients with multiple myeloma","volume":"102","author":"Vacca","year":"2003","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","article-title":"Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis","volume":"114","author":"Zheng","year":"2009","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","article-title":"FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells","volume":"63","author":"Braga","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1172\/JCI88169","article-title":"Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression","volume":"128","author":"Kawano","year":"2018","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1182\/blood-2015-01-623975","article-title":"Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing","volume":"126","author":"Leone","year":"2015","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"Gorgun","year":"2013","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone marrow mesenchymal stem cells are abnormal in multiple myeloma","volume":"21","author":"Corre","year":"2007","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood.V88.6.2219.bloodjournal8862219","article-title":"Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein","volume":"88","author":"Urashima","year":"1996","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V87.5.1928.1928","article-title":"Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells","volume":"87","author":"Urashima","year":"1996","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1158\/1078-0432.CCR-04-0632","article-title":"Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment","volume":"10","author":"Hayashi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1182\/blood-2008-07-170464","article-title":"The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor","volume":"113","author":"Sprynski","year":"2009","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/blood-2004-05-1760","article-title":"VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis","volume":"104","author":"Le Gouill","year":"2004","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/sj.leu.2402875","article-title":"The hepatocyte growth factor\/Met pathway controls proliferation and apoptosis in multiple myeloma","volume":"17","author":"Derksen","year":"2003","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","article-title":"Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment","volume":"66","author":"Tai","year":"2006","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"293479","DOI":"10.1155\/2012\/293479","article-title":"The role of regulatory T cells and TH17 cells in multiple myeloma","volume":"2012","author":"Braga","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.clml.2016.08.003","article-title":"The T cell in myeloma","volume":"16","author":"Joshua","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e47077","DOI":"10.1371\/journal.pone.0047077","article-title":"Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma","volume":"7","author":"Muthu Raja","year":"2012","journal-title":"PLoS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1182\/blood-2016-05-636357","article-title":"The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies","volume":"128","author":"Hoyos","year":"2016","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/nar\/22.7.1147","article-title":"The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed","volume":"22","author":"Laabi","year":"1994","journal-title":"Nucleic Acids Res"},{"key":"B45","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1002\/j.1460-2075.1992.tb05482.x","article-title":"A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma","volume":"11","author":"Laabi","year":"1992","journal-title":"EMBO J"},{"key":"B46","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF AND APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0960-9822(00)00566-2","article-title":"Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI","volume":"10","author":"Marsters","year":"2000","journal-title":"Curr Biol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1084\/jem.192.1.129","article-title":"BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population","volume":"192","author":"Thompson","year":"2000","journal-title":"J Exp Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.4049\/jimmunol.180.6.3655","article-title":"Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL","volume":"180","author":"Benson","year":"2008","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1128\/MCB.21.12.4067-4074.2001","article-title":"B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses","volume":"21","author":"Xu","year":"2001","journal-title":"Mol Cell Biol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"gamma-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.4049\/jimmunol.165.3.1322","article-title":"TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase","volume":"165","author":"Hatzoglou","year":"2000","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1007\/s11033-010-0028-z","article-title":"B-lymphocyte-induced maturation protein1 up-regulates the expression of B-cell maturation antigen in mouse plasma cells","volume":"37","author":"Deng","year":"2010","journal-title":"Mol Biol Rep"},{"key":"B56","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1182\/blood-2011-01-332940","article-title":"Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow","volume":"118","author":"Matthes","year":"2011","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","article-title":"Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model","volume":"13","author":"Neri","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/cbf.3169","article-title":"Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways","volume":"34","author":"Shen","year":"2016","journal-title":"Cell Biochem Funct"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.4049\/jimmunol.175.5.2814","article-title":"B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells","volume":"175","author":"Yang","year":"2005","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood-2006-04-015958","article-title":"Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL","volume":"109","author":"Chiu","year":"2007","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1182\/blood-2002-01-0008","article-title":"A molecular compendium of genes expressed in multiple myeloma","volume":"100","author":"Claudio","year":"2002","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"B67","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"key":"B68","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11523-017-0538-x","article-title":"The role of B-cell maturation antigen in the biology and management of, and as a potential therapeutic target in, multiple myeloma","volume":"13","author":"Sanchez","year":"2018","journal-title":"Target Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1182\/blood-2004-11-4463","article-title":"Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor","volume":"105","author":"Bellucci","year":"2005","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00277-012-1470-x","article-title":"B cell-activating factor: its clinical significance in multiple myeloma patients","volume":"91","author":"Fragioudaki","year":"2012","journal-title":"Ann Hematol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1021\/bi048227k","article-title":"Selectivity of BAFF\/BLyS and APRIL for binding to the TNF family receptors BAFFR\/BR3 and BCMA","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry"},{"key":"B73","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jmb.2004.08.040","article-title":"The crystal structure of a proliferation-inducing ligand, APRIL","volume":"343","author":"Wallweber","year":"2004","journal-title":"J Mol Biol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0609.2009.01262.x","article-title":"APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop","volume":"83","author":"Moreaux","year":"2009","journal-title":"Eur J Haematol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1038\/bcj.2015.3","article-title":"B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?","volume":"5","author":"Hengeveld","year":"2015","journal-title":"Blood Cancer J"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/leu.2015.68","article-title":"Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow","volume":"29","author":"Matthes","year":"2015","journal-title":"Leukemia"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood.V128.22.1148.1148","article-title":"First in human study with GSK2857916, an antibody drug conjugated to microtubule-disrupting agent directed against b-cell maturation antigen (BCMA) in patients with relapsed\/refractory multiple myeloma","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood.V130.Suppl_1.741.741","article-title":"Deep and durable responses in patients (Pts) with relapsed\/refractory multiple myeloma (MM) treated with monotherapy GSK2857916, an antibody drug conjugate against B-cell maturation antigen (BCMA): preliminary results from Part 2 of Study BMA117159","volume":"130","author":"Trudel","year":"2017","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/1538-7445.AM2017-77","article-title":"Preclinical evaluation of HDP-101, an anti-BCMA antibody-drug conjugate","volume":"77","author":"Hechler","year":"2017","journal-title":"Cancer Res"},{"key":"B82","first-page":"3070","article-title":"Preclinical evaluation of Hdp-101, a novel anti-Bcma antibody-drug conjugate, in multiple myeloma","volume":"130","author":"Ko","year":"2017","journal-title":"Blood"},{"key":"B83","first-page":"3153","article-title":"Preclinical evaluation of MEDI2228, a BCMA-targeting pyrrolobenzodiazepine-linked antibody drug conjugate for the treatment of multiple myeloma","volume":"130","author":"Kinneer","year":"2017","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"B85","first-page":"5389","article-title":"Generation of half-life extended anti-BCMA Bite\u00ae antibody construct compatible with once-weekly dosing for treatment of multiple myeloma (MM)","volume":"130","author":"Goyos","year":"2017","journal-title":"Blood"},{"key":"B86","first-page":"524","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor with a CD28 costimulatory moiety cause remissions of poor-prognosis relapsed multiple myeloma","volume":"130","author":"Brudno","year":"2017","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.35.15_suppl.3010","article-title":"First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: updated results","volume":"35","author":"Berdeja","year":"2017","journal-title":"J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"LBA3001","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA3001","article-title":"Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified t cells in patients with refractory\/relapsed multiple myeloma","volume":"35","author":"Fan","year":"2017","journal-title":"J Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nbt0717-599","article-title":"CAR-Ts move beyond B-cell cancers to myeloma","volume":"35","author":"Dolgin","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B90","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.V128.22.1147.1147","article-title":"B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a Phase I Study","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"B91","first-page":"505","article-title":"Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM)","volume":"130","author":"Cohen","year":"2017","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1158\/1538-7445.AM2017-4979","article-title":"Development of KITE-585: a fully human BCMA CAR T-cell therapy for the treatment of multiple myeloma","volume":"77","author":"Adams","year":"2017","journal-title":"Cancer Res"},{"key":"B93","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/blood.V128.22.381.381","article-title":"Preclinical evaluation of allogeneic anti-bcma chimeric antigen receptor t cells with safety switch domains and lymphodepletion resistance for the treatment of multiple myeloma","volume":"128","author":"Boldajipour","year":"2016","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1182\/blood.V128.22.4557.4557","article-title":"Development of novel non-immunoglobulin centyrin-based cars (CARTyrins) targeting human Bcma","volume":"128","author":"Barnett","year":"2016","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.V128.22.2127.2127","article-title":"A novel BCMA-specific, centyrin-based CAR-T product for the treatment of multiple myeloma","volume":"128","author":"Hermanson","year":"2016","journal-title":"Blood"},{"key":"B96","first-page":"3068","article-title":"B-cell maturation antigen (BCMA)-specific, Centyrin\u2122-based, PiggyBac\u2122-transposed CAR-T memory stem cells are effective against p53\u2013\/\u2013 and patient-derived multiple myeloma tumors","volume":"130","author":"Mathur","year":"2017","journal-title":"Blood"},{"key":"B97","first-page":"504","article-title":"T cells expressing anti-B-cell maturation antigen (BCMA) chimeric antigen receptors with antigen recognition domains made up of only single human heavy chain variable domains specifically recognize Bcma and eradicate tumors in mice","volume":"130","author":"Lam","year":"2017","journal-title":"Blood"},{"key":"B98","first-page":"3067","article-title":"CD8+ anti-Bcma mRNA CAR T-cells effectively kill human multiple myeloma cells in vitro and in vivo","volume":"130","author":"Lin","year":"2017","journal-title":"Blood"},{"key":"B99","first-page":"503","article-title":"Production of universal anti-Bcma CAR-T cells with reduced alloreactivity, but potent effector function for the treatment of multiple myeloma","volume":"130","author":"Wang","year":"2017","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.V128.22.383.383","article-title":"Preclinical evaluation of a potent anti-BCMA CD3 bispecific molecule for the treatment of multiple myeloma","volume":"128","author":"Panowski","year":"2016","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood.V128.22.2096.2096","article-title":"New insights into the mechanism of action (MoA) of first-in-class IgG-based Bcma T-cell bispecific antibody (TCB) for the treatment of multiple myeloma (MM)","volume":"128","author":"Moreno","year":"2016","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1182\/blood.V128.22.2116.2116","article-title":"Development of a new BCMAxCD3 Duobody \u00ae antibody for multiple myeloma","volume":"128","author":"Pillarisetti","year":"2016","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1158\/1538-7445.AM2017-5671","article-title":"AFM26 \u2013 a novel CD16a-directed bispecific TandAb targeting bcma for multiple myeloma","volume":"77","author":"Gantke","year":"2017","journal-title":"Cancer Res"},{"key":"B104","first-page":"3082","article-title":"AFM26 \u2013 targeting B cell maturation antigen (BCMA) for NK cell-mediated immunotherapy of multiple myeloma","volume":"130","author":"Gantke","year":"2017","journal-title":"Blood"},{"key":"B105","first-page":"501","article-title":"T Cell engagement without cytokine storm: a novel Bcma x CD3 antibody killing myeloma cells with minimal cytokine secretion","volume":"130","author":"Buelow","year":"2017","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1182\/blood.V128.22.4513.4513","article-title":"Trispecific antibodies for selective CD16A-directed NK-cell engagement in multiple myeloma","volume":"128","author":"Gantke","year":"2016","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","article-title":"Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry","volume":"17","author":"McCombs","year":"2015","journal-title":"AAPS J"},{"key":"B108","doi-asserted-by":"publisher","first-page":"21549","DOI":"10.1074\/jbc.271.35.21549","article-title":"Amanitin greatly reduces the rate of transcription by RNA polymerase II ternary complexes but fails to inhibit some transcript cleavage modes","volume":"271","author":"Rudd","year":"1996","journal-title":"J Biol Chem"},{"key":"B109","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-1-62703-541-5_11","article-title":"Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers","volume":"1045","author":"Bhakta","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-specific antibody drug conjugates for cancer therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"MAbs"},{"key":"B111","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","article-title":"Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class","volume":"30","author":"Brischwein","year":"2007","journal-title":"J Immunother"},{"key":"B113","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol Immunol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.1073\/pnas.0811427106","article-title":"Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10","volume":"106","author":"Klein","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B115","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B116","first-page":"506","article-title":"Combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for RRMM: initial safety and efficacy report from a Clinical Pilot Study","volume":"130","author":"Yan","year":"2017","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"6856","DOI":"10.1182\/blood-2011-01-330852","article-title":"Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas","volume":"117","author":"Guadagnoli","year":"2011","journal-title":"Blood"},{"key":"B118","first-page":"1827","article-title":"Bion-1301, a first-in-class APRIL neutralizing antibody for the treatment of multiple myeloma: preclinical safety, and analysis of pharmacokinetics \u2013 pharmacodynamics relationship","volume":"130","author":"Dulos","year":"2017","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1158\/1535-7163.MCT-07-0464","article-title":"Antibody targeting of B-cell maturation antigen on malignant plasma cells","volume":"6","author":"Ryan","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"B120","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.V130.Suppl_1.740.740","article-title":"Durable clinical responses in heavily pretreated patients with relapsed\/refractory multiple myeloma: updated results from a Multicenter Study of bb2121 Anti-Bcma CAR T cell therapy","volume":"130","author":"Berdeja","year":"2017","journal-title":"Blood"},{"key":"B121","first-page":"3115","article-title":"Effective treatment of relapsed\/refractory multiple myeloma including extramedullary involvement by BCMA-specific chimeric antigen receptor-modified T cells","volume":"130","author":"Mi","year":"2017","journal-title":"Blood"},{"key":"B122","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"B123","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B124","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"B125","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"B127","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B129","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1182\/blood-2007-02-072843","article-title":"Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes","volume":"110","author":"Quintarelli","year":"2007","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/stem.433","article-title":"An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies","volume":"28","author":"Ramos","year":"2010","journal-title":"Stem Cells"},{"key":"B132","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"18950","DOI":"10.1038\/srep18950","article-title":"Design of chimeric antigen receptors with integrated controllable transient functions","volume":"6","author":"Juillerat","year":"2016","journal-title":"Sci Rep"},{"key":"B134","doi-asserted-by":"publisher","first-page":"aab4077","DOI":"10.1126\/science.aab4077","article-title":"Remote control of therapeutic T cells through a small molecule-gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science"},{"key":"B135","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1039\/c4np00036f","article-title":"Chemistry and biology of tubulysins: antimitotic tetrapeptides with activity against drug resistant cancers","volume":"32","author":"Murray","year":"2015","journal-title":"Nat Prod Rep"},{"key":"B136","doi-asserted-by":"publisher","first-page":"13817","DOI":"10.1073\/pnas.1408124111","article-title":"A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs","volume":"111","author":"Prota","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B137","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.tibtech.2017.03.001","article-title":"Bioproduction of antibody-drug conjugate payload precursors by engineered cell factories","volume":"35","author":"Wang","year":"2017","journal-title":"Trends Biotechnol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect?","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"B141","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-11-1417","article-title":"Antibody conjugate therapeutics: challenges and potential","volume":"17","author":"Teicher","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"B144","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"e20787","DOI":"10.1371\/journal.pone.0020787","article-title":"Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival","volume":"6","author":"Maia","year":"2011","journal-title":"PLoS One"},{"key":"B146","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood-2005-09-3552","article-title":"B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia","volume":"107","author":"Elsawa","year":"2006","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1038\/sj.onc.1207350","article-title":"Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor","volume":"23","author":"Deshayes","year":"2004","journal-title":"Oncogene"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01821\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:35:43Z","timestamp":1661733343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01821\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,10]]},"references-count":147,"alternative-id":["10.3389\/fimmu.2018.01821"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01821","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,10]]},"article-number":"1821"}}